指南与共识流行病学与生物统计临床试验与 GCP

用于宫颈筛查的自采样人乳头瘤病毒检测相对敏感性验证的分阶段设计推荐

Staged design recommendations for validating relative sensitivity of self-sample human papillomavirus tests for cervical screening.
指南 / 共识 · J Clin Epidemiol · 2023-12-07

为稳健评估宫颈筛查中自采样人乳头瘤病毒(HPV)检测的新方法,该研究评估了配对研究设计在检测高级别宫颈上皮内瘤变时自采样与临床医生采样相对敏感性的适用性,共考虑五种设计(D1-D5)。结论认为难以给出通用最优设计推荐,分阶段验证可能有用,以D5作为D1-D4的准入筛选。

要点

  • D1需最大样本量且需转诊自采样阳性而医生采样阴性女性,分析简单。
  • D2样本量小得多且不改变临床实践,可用于 rule-in 检测因估计偏保守。
  • D5较宽松,可用于 rule-out 自采样检测,分阶段验证或以D5作为D1-D4的准入筛选。

核心结论

  • 对最佳研究设计给出通用推荐具有挑战性,分阶段验证可能有用,以D5作为D1-D4的准入筛选。

研究设计与样本

  • 评估配对研究设计,比较自采样与临床医生采样在检测高级别宫颈上皮内瘤变中的相对敏感性。

主要发现

  • D1分析简单但需最大样本量,且需转诊自采样阳性而医生采样阴性的女性。
  • D2样本量小得多且不改变临床实践,因估计偏保守(不利于自采样)可用于 rule-in 检测。
  • D3减轻该偏倚但需第二次医生采样样本。
  • D4仅在已开展自采样的地方可行。
  • 较宽松的D5可用于 rule-out 自采样检测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To ensure that the emerging methods for human papillomavirus (HPV) testing on self-collected samples in cervical screening are evaluated robustly. STUDY DESIGN AND SETTING: We assess paired study designs for relative sensitivity of self-collected vs. traditional clinician-collected samples in detection of high-grade cervical intraepithelial neoplasia. RESULTS: Designs considered are (D1) both samples at screening, with clinical actions triggered by HPV positivity; (D2) offering a self-sample test to clinician-collected HPV-positive women; (D3) as D2 but using a repeat clinician-sample as comparator; (D4) offering a choice of self- vs. clinician-sampling, and the alternative test in HPV-positive women; (D5) paired samples at referral appointment. D1 is simple to analyze but requires the largest sample size and referral of self-sample positive, clinician-sample negative women. D2 requires a much smaller sample size, and no change to clinical practice, and could be used to rule-in a test because estimates are conservative (against self-sampling). D3 mitigates this bias but requires a second clinician sample. D4 is only manageable where self-sampling already occurs. The liberal D5 might be used to rule-out a self-sampling test. CONCLUSION: A universal recommendation for an optimal study design is challenging. Staged validation might be useful with D5 as a gatekeeper for D1-D4.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Brentnall AR, Cuschieri K, Sargent A, et al. Staged design recommendations for validating relative sensitivity of self-sample human papillomavirus tests for cervical screening. J Clin Epidemiol. 2023. PMID: 38065518. doi:10.1016/j.jclinepi.2023.111227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。